Dyne Therapeutics, Inc. (DYN) Revenue History
Annual and quarterly revenue from 2007 to present
DYN Revenue Over Time (2007–2025)
DYN Revenue Growth History
3 of 11 years with positive growth- FY2007 revenue growth
- N/A
- FY2008 revenue growth
- +14.4%
- FY2009 revenue growth
- -30.5%
- FY2010 revenue growth
- -5.9%
- FY2011 revenue growth
- -31.8%
- FY2012 revenue growth
- -99.8%
- FY2013 revenue growth
- +0.0%
- FY2014 revenue growth
- +48766.7%
- FY2015 revenue growth
- -42.6%
- FY2016 revenue growth
- +62.2%
- FY2017 revenue growth
- -63.0%
- FY2018 revenue growth
- -100.0%
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $0 | — |
| Q2 2026 | $0 | — |
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
Multi-year avg. share of annual revenue by fiscal quarter
DYN Revenue Analysis (2007–2025)
Current Revenue & Growth
As of November 7, 2026, Dyne Therapeutics, Inc. (DYN) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2026) recorded $0 in revenue
Historical Growth Trajectory
DYN's historical revenue data shows various trends over time. Dyne Therapeutics, Inc.'s highest annual revenue of $3.55 billion was recorded in 2008.
Peer Comparison
Compared to Healthcare sector peers — including SRPT (-18.9% YoY), CRSP (-33.1% YoY), and BMRN (+18.1% YoY). Compare DYN vs SRPT →
DYN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| DYNCurrent | $0 | - | - | - | |
 SRPT | $2.2B | -18.9% | +32.4% | -29.9% | |
 CRSP | $4M | -33.1% | +37.3% | -16191.4% | |
 BMRN | $3.2B | +18.1% | +11.6% | 16.6% | |
 RARE | $673M | +15.8% | +19.9% | -79.5% | |
 IONS | $944M | -7.4% | +5.3% | -40.5% |
DYN Historical Revenue Data (2007–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-2,049,000 | - | $-468,184,000 | - |
| 2024 | $0 | - | $-2,243,000 | - | $-343,886,000 | - |
| 2023 | $0 | - | $-2,461,000 | - | $-242,162,000 | - |
| 2022 | $0 | - | $0 | - | $-170,962,000 | - |
| 2021 | $0 | - | $0 | - | $-150,025,000 | - |
| 2020 | $0 | - | $-700,000 | - | $-58,647,000 | - |
| 2019 | $0 | - | $-271,000 | - | $-13,826,000 | - |
| 2018 | $0 | -100.0% | $-24,000 | - | $-4,795,000 | - |
| 2017 | $506.0M | -63.0% | $-2,426,000,000 | -479.4% | $-412,000,000 | -81.4% |
| 2016 | $1.37B | +62.2% | $-915,000,000 | -67.0% | $-640,000,000 | -46.9% |
| 2015 | $842.0M | -42.6% | $-1,186,000,000 | -140.9% | $64.0M | 7.6% |
| 2014 | $1.47B | +48766.7% | $321.0M | 21.9% | $-318,000,000 | -21.7% |
| 2013 | $3.0M | +0.0% | $-1,142,000,000 | -38066.7% | $-318,000,000 | -10600.0% |
| 2012 | $3.0M | -99.8% | $-265,000,000 | -8833.3% | $714.0M | 23800.0% |
| 2011 | $1.58B | -31.8% | $622.0M | 39.2% | $-236,000,000 | -14.9% |
DYN Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
19+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
DYN — Frequently Asked Questions
Quick answers to the most common questions about buying DYN stock.
Is DYN's revenue growth accelerating or slowing?
DYN TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is DYN's revenue history from 2007 to 2026?
Dyne Therapeutics, Inc. (DYN) revenue history spans 2007 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is DYN's long-term revenue growth rate (CAGR)?
Dyne Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for DYN.
Why does DYN's quarterly revenue fluctuate?
DYN quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Dyne Therapeutics, Inc.'s revenue data from 2007 to 2026 shows full historical quarterly detail on this page.
How is DYN's revenue distributed by segment?
DYN reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does DYN's revenue compare to industry peers?
Dyne Therapeutics, Inc. (DYN) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.